In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, reflects on the gap between sponsor expectations and statistical reality, drawing on lessons from the COVID era to argue for more ...

In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, examines the most common threats to trial data reliability ...

A new review of multiple studies suggests that regular physical activity can significantly lower anxiety and depressed moods ...

The literature on physician-mediated interventions to reduce costs is scant and provides little guidance on effective ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Allogene Therapeutics Inc (ALLO) extends its cash runway into 2028 while focusing on pivotal clinical milestones and ...

There was some evidence that cannabinoids can reduce symptoms of cannabis use disorder, insomnia, tic or Tourette's syndrome, and autism spectrum disorder, but the quality of this evidence was ...

Objective: To conduct a cost-effectiveness analysis comparing behavioral health integration (BHI) in primary care vs clinical ...

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder affecting children and adults.

G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...